Neurocrine v. Crystal Pharmaceutical & Sandoz: Dismissed Without Prejudice After 717 Days
Neurocrine Biosciences filed suit in Delaware against Crystal Pharmaceutical (Suzhou), Crystal Pharmatech, and Sandoz over four patents covering valbenazine tosylate capsule formulations. After nearly two years of litigation, all claims and counterclaims were stipulated dismissed without prejudice, with the court retaining jurisdiction over any unresolved disputes.
Valbenazine patent battle ends by stipulation — all claims preserved
On October 18, 2021, Neurocrine Biosciences, Inc. filed a patent infringement action in the U.S. District Court for the District of Delaware (Case No. 1:21-cv-01464) against Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., and Sandoz, Inc. The complaint concerned four U.S. patents — US11026931B2, US11040029B2, US11026939B2, and US10993941B2 — asserted against valbenazine tosylate capsules equivalent to 40 mg and 80 mg doses.
The recorded basis of termination is dismissal without prejudice. The docket order states that, pursuant to Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c), the parties stipulated that all claims, counterclaims, and affirmative defenses are dismissed without prejudice and without costs, disbursements, or attorneys' fees to any party. The stipulation further records that the District of Delaware retains jurisdiction to enforce and resolve disputes relating to the parties' resolution of the actions.
The case ran for 717 days before dismissal — consistent with a resolution reached ahead of trial in an ANDA-type pharmaceutical patent dispute. The retention-of-jurisdiction clause suggests the parties contemplated some ongoing agreement, though the specific terms of any such agreement are not disclosed in the available record. Because the dismissal is without prejudice, Neurocrine retains the ability to reassert these patents, and all defendants retain their defenses, should circumstances change.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 717 days
717 days from filing to dismissal — a typical ANDA patent litigation timeline before trial
US11026931B2 and three further patents — valbenazine tosylate formulations
Any company developing a generic or follow-on valbenazine tosylate product — whether through an ANDA, 505(b)(2), or NDA pathway — should conduct a thorough freedom-to-operate analysis against all four asserted patents. The without-prejudice dismissal leaves all claims intact. Given that the court retained jurisdiction, the enforcement risk from this portfolio has not dissipated.
Official order — verbatim text
The stipulation of dismissal, entered under FRCP 41(a)(1)(A)(ii) and 41(c), terminates all claims, counterclaims, and affirmative defenses between the parties without prejudice and without any cost allocation. The court's express retention of jurisdiction to enforce and resolve disputes relating to the parties' resolution suggests the dismissal accompanies some form of negotiated arrangement, though the content of that arrangement is not disclosed in the available record.
Dismissed without prejudice: what the stipulated outcome means for both parties
Rule 41 stipulated dismissal — all claims preserved, no merits ruling
Under FRCP 41(a)(1)(A)(ii) and 41(c), the parties jointly filed a stipulation of dismissal without prejudice. This procedural mechanism requires no court approval and takes effect immediately upon filing. A without-prejudice dismissal means no judgment on the merits was entered — Neurocrine may refile these patent claims, and the defendants' invalidity and non-infringement defenses remain intact. The court expressly retained jurisdiction over disputes arising from the parties' resolution.
No merits adjudicationNeurocrine's four patents survive — right to refile preserved
A dismissal without prejudice does not extinguish Neurocrine's patent rights or its ability to enforce them. The four asserted patents — covering valbenazine tosylate capsule formulations — remain in force as issued. Neurocrine retains the option to refile infringement claims if the defendants' generic product enters the market or if the parties' resolution breaks down. The court's retained jurisdiction clause may also provide a mechanism to address any future disputes without a full re-filing.
Patents remain enforceableCrystal Pharmaceutical and Sandoz exit without prejudice — no admission of infringement
Crystal Pharmaceutical (Suzhou), Crystal Pharmatech, and Sandoz obtained dismissal of all claims against them without any finding of infringement or validity. Their counterclaims and affirmative defenses are equally dismissed without prejudice, preserving all invalidity and non-infringement arguments for potential future proceedings. The absence of any cost or fee award means no financial penalty was imposed on any party.
No infringement findingGeneric valbenazine market entry remains contingent on undisclosed terms
The dismissal without prejudice, combined with the court's retained jurisdiction, is consistent with a negotiated resolution — though the specific terms are not disclosed in the available record. For competitors and market observers, the practical effect on Crystal Pharmaceutical's and Sandoz's ability to commercialise generic valbenazine tosylate capsules depends on any such undisclosed arrangements. Companies monitoring the valbenazine IP landscape should treat these four patents as still active enforcement assets.
Market entry timing uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Neurocrine Biosciences, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Company | /Search in Eureka ↗ |
| Co-Defendant | Sandoz, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Crystal Pharmatech Co., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Erin M. Sommers | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | James B. Monroe | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeanette M. Roorda | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lauren J. Dowty | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | C. Kyle Musgrove | Attorney | Counsel for Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Attorney | Counsel for Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | John C. Phillips | Attorney | Counsel for Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Defendant counsel | Scott A. Cunning , II | Attorney | Counsel for Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | PRO SE | Law Firm | Representing Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Phillips, Goldman, McLaughlin & Hall PA | Law Firm | Representing Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Crystal Pharmaceutical (Suzhou) Co., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the valbenazine and VMAT2 inhibitor patent space
Forward-looking IP and R&D intelligence on Neurocrine's valbenazine portfolio, VMAT2 inhibitor filing trends, and the competitive landscape for CNS movement disorder therapies.
Neurocrine's valbenazine patent portfolio depth and filing trajectory
Neurocrine's assertion of four formulation patents from the US16/US17 application series signals an active life-cycle management strategy around Ingrezza. Monitoring Neurocrine's continuing applications and divisionals in this family can reveal the next layer of formulation or method-of-use protection likely to anchor future ANDA litigation.
Portfolio life-cycle managementVMAT2 inhibitor filing trends: who is patenting next-generation candidates
Beyond valbenazine, the VMAT2 inhibitor class — covering tardive dyskinesia and other hyperkinetic movement disorders — is attracting active patenting. Tracking filing activity across composition-of-matter, polymorph, and formulation claims in this class can identify emerging competitors and white-space opportunities before clinical-stage announcements.
VMAT2 inhibitor landscapeCrystal Pharmaceutical's solid-state chemistry IP in generic CNS products
Crystal Pharmaceutical (Suzhou) and Crystal Pharmatech operate in the polymorphic and solid-state formulation space for generic APIs. Reviewing their patent filings and applications in the CNS and small-molecule formulation domain can reveal whether they are building proprietary crystal form IP that could support future ANDA filings independent of innovator patents.
Generic solid-state IP activityAdjacent formulation approaches not covered by the four asserted patents
The asserted patents focus on valbenazine tosylate capsule forms. White space may exist around alternative salt forms, extended-release or modified-release formulations, combination products, or novel delivery mechanisms for VMAT2 inhibitors — areas where design-around or innovation strategies could yield patentable differentiation.
CNS formulation white spaceSimilar ANDA patent cases in Delaware District Court — CNS formulations
Explore comparable Hatch-Waxman infringement actions in the Delaware District Court involving branded CNS or small-molecule formulation patents against generic challengers.
What this case signals for the valbenazine and ANDA patent landscape
Four Neurocrine valbenazine patents remain live enforcement tools after this without-prejudice resolution in Delaware.
Without-prejudice dismissal preserves Neurocrine's full enforcement posture
Because no judgment on the merits was entered, all four asserted patents retain their presumption of validity and remain available for future enforcement. Any generic entrant — not just the current defendants — should treat these patents as active blocking IP. An FTO analysis against the valbenazine tosylate formulation space remains necessary.
Court-retained jurisdiction signals an ongoing arrangement between the parties
The stipulation's express retention-of-jurisdiction clause suggests the parties anticipated the need for a mechanism to resolve future disputes without re-filing. This is consistent with pharmaceutical patent settlements that include market-entry timing or licensing provisions — though the specific terms are not disclosed in the available record.
Neurocrine v Crystal — key questions answered
Neurocrine asserted four patents: US11026931B2, US11040029B2, US11026939B2, and US10993941B2. All four relate to valbenazine tosylate capsule formulations equivalent to 40 mg and 80 mg doses, the form commercialised as Ingrezza.
The recorded basis of termination is dismissal without prejudice. The docket order states the parties stipulated under FRCP 41(a)(1)(A)(ii) and 41(c) to dismiss all claims, counterclaims, and affirmative defenses without prejudice and without costs or fees to any party. The District of Delaware retained jurisdiction over any disputes relating to the parties' resolution.
A dismissal without prejudice does not constitute a judgment on the merits and does not extinguish patent rights. Neurocrine retains the right to refile infringement claims based on the same four patents if circumstances warrant. The patents remain in force as issued.
The stipulation states that the U.S. District Court for the District of Delaware retains jurisdiction to enforce and resolve disputes relating to the parties' resolution of the actions. The specific terms of that resolution are not disclosed in the available record, so the precise scope of the retained jurisdiction and the underlying arrangement cannot be characterised further from the public record.
Sandoz was named as a U.S. commercial defendant alongside the Crystal entities, which are manufacturers. This is consistent with an ANDA supply and distribution structure where the foreign manufacturer supplies the product and a U.S. entity handles commercialisation. The case's dismissal without prejudice means no determination was made on whether Sandoz or the Crystal defendants infringed the asserted patents.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.